JP2017510400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510400A5 JP2017510400A5 JP2016575315A JP2016575315A JP2017510400A5 JP 2017510400 A5 JP2017510400 A5 JP 2017510400A5 JP 2016575315 A JP2016575315 A JP 2016575315A JP 2016575315 A JP2016575315 A JP 2016575315A JP 2017510400 A5 JP2017510400 A5 JP 2017510400A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- self
- solution
- assembling peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 104
- 238000000034 method Methods 0.000 claims description 103
- 239000000203 mixture Substances 0.000 claims description 82
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000000872 buffer Substances 0.000 claims description 27
- 210000004072 lung Anatomy 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 21
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 18
- 230000004888 barrier function Effects 0.000 claims description 18
- 239000001110 calcium chloride Substances 0.000 claims description 18
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 18
- 239000000017 hydrogel Substances 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 230000004962 physiological condition Effects 0.000 claims description 11
- 239000002872 contrast media Substances 0.000 claims description 8
- 206010006440 Bronchial obstruction Diseases 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 210000000621 bronchi Anatomy 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 210000003437 trachea Anatomy 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 206010067171 Regurgitation Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 description 81
- 235000002639 sodium chloride Nutrition 0.000 description 32
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 18
- -1 iron ion Chemical class 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 9
- 239000001103 potassium chloride Substances 0.000 description 9
- 235000011164 potassium chloride Nutrition 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 229910001414 potassium ion Inorganic materials 0.000 description 6
- 229910001415 sodium ion Inorganic materials 0.000 description 6
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 229940006477 nitrate ion Drugs 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461950529P | 2014-03-10 | 2014-03-10 | |
| US61/950,529 | 2014-03-10 | ||
| US201461953146P | 2014-03-14 | 2014-03-14 | |
| US61/953,146 | 2014-03-14 | ||
| PCT/US2015/019740 WO2015138475A1 (en) | 2014-03-10 | 2015-03-10 | Self-assembling peptides as bronchial obstruction agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510400A JP2017510400A (ja) | 2017-04-13 |
| JP2017510400A5 true JP2017510400A5 (cg-RX-API-DMAC7.html) | 2018-05-31 |
| JP6554121B2 JP6554121B2 (ja) | 2019-07-31 |
Family
ID=52737414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575315A Expired - Fee Related JP6554121B2 (ja) | 2014-03-10 | 2015-03-10 | 気管支閉鎖剤としての自己組織化ペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20170173221A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3116523B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6554121B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2706492T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015138475A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101670099B1 (ko) | 2008-10-06 | 2016-10-27 | 가부시끼가이샤 쓰리디 매트릭스 | 조직 폐색제 |
| EP2869903B1 (en) | 2012-07-06 | 2018-11-28 | 3-D Matrix Ltd. | Fill-finish process for peptide solutions |
| CN117138022A (zh) * | 2014-03-10 | 2023-12-01 | 三维矩阵有限责任公司 | 自组装肽组合物 |
| EP3116524B1 (en) | 2014-03-10 | 2018-11-28 | 3-D Matrix Ltd. | Autoassembling peptides for the treatment of pulmonary bulla |
| BR112016019510A2 (pt) | 2014-03-10 | 2017-10-24 | 3 D Matrix Ltd | esterilização e filtração de composições de peptídeos |
| US10814038B2 (en) | 2016-01-06 | 2020-10-27 | 3-D Matrix, Ltd. | Combination compositions |
| CN111712230B (zh) | 2017-12-15 | 2024-04-26 | 立美基股份有限公司 | 表面活性剂肽纳米结构及在药物递送中的用途 |
| WO2020008377A2 (en) * | 2018-07-03 | 2020-01-09 | 3-D Matrix, Ltd. | Ionic self-assembling peptides |
| IL304283B2 (en) | 2020-03-31 | 2024-12-01 | 3 D Matrix Ltd | Sterilization of self-assembling peptides by irradiation |
| JP2023538536A (ja) * | 2020-08-10 | 2023-09-08 | ジェルフォーメッド，インク． | 自己組織化両親媒性ペプチドハイドロゲルの局所的および非経口的な使用および投与 |
| US20250281676A1 (en) * | 2020-08-10 | 2025-09-11 | Gel4Med, Inc. | Delivery of cells and tissues with self-assembling peptide hydrogel materials |
| BR112023002562A2 (pt) * | 2020-08-10 | 2023-03-14 | Gel4Med Inc | Hidrogéis de peptídeo anfifílico de automontagem |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020147462A1 (en) * | 2000-09-11 | 2002-10-10 | Closure Medical Corporation | Bronchial occlusion method and apparatus |
| AU2003249606A1 (en) * | 2002-05-13 | 2003-12-02 | Massachusetts Institute Of Technology | Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof |
| KR20110091019A (ko) * | 2006-04-25 | 2011-08-10 | 메사추세츠 인스티튜트 오브 테크놀로지 | 오염물, 체액 또는 다른 실재물의 이동 및/또는 다른 생리학적 상태에 영향을 주기 위한 조성물 및 방법 |
| KR101670099B1 (ko) * | 2008-10-06 | 2016-10-27 | 가부시끼가이샤 쓰리디 매트릭스 | 조직 폐색제 |
| JP6034868B2 (ja) * | 2011-09-02 | 2016-11-30 | 株式会社スリー・ディー・マトリックス | 胸部の空気漏れ閉塞のための両親媒性ペプチド |
| EP3116524B1 (en) * | 2014-03-10 | 2018-11-28 | 3-D Matrix Ltd. | Autoassembling peptides for the treatment of pulmonary bulla |
-
2015
- 2015-03-10 EP EP15712232.6A patent/EP3116523B1/en not_active Not-in-force
- 2015-03-10 WO PCT/US2015/019740 patent/WO2015138475A1/en not_active Ceased
- 2015-03-10 ES ES15712232T patent/ES2706492T3/es active Active
- 2015-03-10 US US15/124,639 patent/US20170173221A1/en not_active Abandoned
- 2015-03-10 JP JP2016575315A patent/JP6554121B2/ja not_active Expired - Fee Related
-
2021
- 2021-11-18 US US17/529,600 patent/US20220160939A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510400A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513928A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513927A5 (cg-RX-API-DMAC7.html) | ||
| JP6554121B2 (ja) | 気管支閉鎖剤としての自己組織化ペプチド | |
| US20220008335A1 (en) | Implants and constructs including hollow fibers | |
| ES2261735T3 (es) | Sistema para la administracion de una formulacion de tobramicina. | |
| ES2762250T5 (es) | Tratamiento combinado del cáncer | |
| JP2019528320A5 (cg-RX-API-DMAC7.html) | ||
| JP2013501224A5 (cg-RX-API-DMAC7.html) | ||
| JP6545727B2 (ja) | 肺大気胞を治療するための自発組織化ペプチド | |
| JP2022008403A5 (cg-RX-API-DMAC7.html) | ||
| JP2016515113A5 (cg-RX-API-DMAC7.html) | ||
| KR20110081204A (ko) | 트레프로스티닐의 폐 심부 전달 | |
| JP2015129129A (ja) | 肺高血圧症のための治療 | |
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| WO2015127368A1 (en) | Hypotonic microbicidal formulations and methods of use | |
| ES2774773T3 (es) | Agente terapéutico para la osteoporosis | |
| RU2020109705A (ru) | Соединения и их фармацевтические композиции для применения в лечении фиброзных заболеваний | |
| Ursella et al. | The use of non-invasive ventilation in the treatment of acute cardiogenic pulmonary edema. | |
| JP2019518569A5 (cg-RX-API-DMAC7.html) | ||
| HRP20161634T1 (hr) | Novi pripravak alfentanila za liječenje akutne boli | |
| ES2661173T3 (es) | Combinación de solución de aminoácidos y un derivado de gelatina para inhibir la absorción renal | |
| JP2019503335A (ja) | ジメチルアミノミケリオリドの使用 | |
| JP2010506855A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020071448A1 (ja) | 吸入粉末剤、その評価方法及びその用途 |